Management and Diagnosis of Empagliflozin-Induced Burning Mouth Syndrome: A Case Report
Abstract
Burning mouth syndrome (BMS) poses a significant clinical challenge. Patients often present with symptoms that can severely affect their quality of life, leading to anxiety, depression, and social withdrawal. The etiology of BMS remains poorly understood, which complicates its diagnosis and treatment. This case report describes an 80-year-old woman who presented with BMS following the administration of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for glycemic control, along with its benefits in the progression and prognosis of cardiac insufficiency and chronic renal disease. Despite multiple treatments, her symptoms persisted until empagliflozin withdrawal, resulting in significant improvement at the six-month follow-up. This report suggests a potential association between empagliflozin and BMS, underscoring the need for clinicians to be vigilant regarding drug-related etiologies in the diagnosis and management of oral symptoms.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.